Antibacterial Nanoparticles Therapeutic (ANT) Study
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Defense Health Agency (DHA), specifically the Walter Reed Army Institute of Research (WRAIR), Bacterial Diseases Branch (BDB), is conducting a Sources Sought effort for an Antibacterial Nanoparticles Therapeutic (ANT) Study. The purpose is to gather information for planning to test innovative antibacterial nanoparticles (PhANPs) against combat-relevant multi-drug resistant (MDR) strains of Pseudomonas aeruginosa. This RFI is not a solicitation. Responses are due by April 1, 2026.
Scope of Work
The BDB seeks to conduct a study to test PhANPs, a unique technology patented by the University of Notre Dame (US-12161725-B2), to bring novel therapeutics to military healthcare. The contractor shall provide non-personal Research and Development (R&D) effort, including qualified research personnel, appropriate laboratory facilities, and all necessary laboratory and research-related materials and supplies. Key requirements include:
- Producing and conjugating SilverGold Nanoparticles to meet three specific milestones.
- Delivering specific quantities of lyophilized nanoparticles, shipped on ice, with associated Quality Control (QC) certificates.
- Providing documentation on fundamental properties (purity, composition, size, morphology, stability) and antibacterial effectiveness (MIC, MBC, time-kill kinetics, spectrum of activity) of the nanoparticles.
Contract & Timeline
- Opportunity Type: Sources Sought / Request for Information (RFI)
- NAICS Code: 541713 - Research and Development in Nanotechnology
- Response Due: April 1, 2026, 2:00 PM EDT
- Published Date: March 18, 2026
- Contracting Office: Defense Health Agency Contracting Activity (DHACA)
- Place of Performance: Silver Spring, MD
Submission & Evaluation
Interested parties should submit responses electronically in Microsoft Word or Adobe PDF format. White papers should not exceed 3 pages, excluding a cover page that includes specific contact and organizational details. A capabilities statement is required. Information received will be treated as business confidential if marked.
Eligibility
Responses from all capable and qualified sources are encouraged. No specific set-aside is designated for this market research.
Additional Notes
This notice is for planning purposes only and does not constitute a solicitation or commitment by the Government. Responses are not offers and will not be returned. Responders are solely responsible for all expenses associated with responding. No hardcopies will be accepted, and no written solicitation document is available at this time. Questions should be directed via email to Ms. Linda Hinson or Mr. Sharew Hailu by April 1, 2026.